

REMARKS


Claims 1-50 are pending in this application. Claims 23 and 29 have been amended by the current amendment. The amendments to claims 23 and 29 insert sequence identifiers in adherence with 37 C.F.R. §§1.821 to 1.825.

Applicants request entry of this amendment in adherence with 37 C.F.R. §§1.821 to 1.825. This amendment is accompanied by a floppy disk containing the above named sequences, SEQ ID NOS:1-23, in computer readable form, and a paper copy of the sequence information which has been printed from the floppy disk.

The information contained in the computer readable disk was prepared through the use of the software program "PatentIn" and is identical to that of the paper copy. This amendment contains no new matter.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,


Laurence J. Hyman
Reg. No. 47,651

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
Attachments
LJH:dmw
60102023 v1



SEQUENCE LISTING

<10> Sherman, Irwin
Winograd, Enrique
The Regents of the University of California

<120> Peptides Which Generate Antibodies Resulting in Lysis
of Pathologically Adherent Erythrocytes

<130> 023070-140500US

<140> US 10/663,215

<141> 2003-09-15

<160> 23

<170> PatentIn Ver. 2.1

<210> 1

<211> 911

<212> PRT

<213> Homo sapiens

<220>

<223> human anion exchange protein 1 (AE1), band 3
protein

<400> 1

Met Glu Glu Leu Gln Asp Asp Tyr Glu Asp Met Met Glu Glu Asn Leu
1 5 10 15

Glu Gln Glu Glu Tyr Glu Asp Pro Asp Ile Pro Glu Ser Gln Met Glu
20 25 30

Glu Pro Ala Ala His Asp Thr Glu Ala Thr Ala Thr Asp Tyr His Thr
35 40 45

Thr Ser His Pro Gly Thr His Glu Val Tyr Val Glu Leu Gln Glu Leu
50 55 60

Val Met Asp Glu Lys Asn Gln Glu Leu Arg Trp Met Glu Ala Ala Arg
65 70 75 80

Trp Val Gln Leu Glu Glu Asn Leu Gly Glu Asn Gly Ala Trp Gly Arg
85 90 95

Pro His Leu Ser His Leu Thr Phe Trp Ser Leu Leu Glu Leu Arg Arg
100 105 110

Val Phe Thr Lys Gly Thr Val Leu Leu Asp Leu Gln Glu Thr Ser Leu
115 120 125

Ala Gly Val Ala Asn Gln Leu Leu Asp Arg Phe Ile Phe Glu Asp Gln
130 135 140

Ile Arg Pro Gln Asp Arg Glu Glu Leu Leu Arg Ala Leu Leu Leu Lys
145 150 155 160

His Ser His Ala Gly Glu Leu Glu Ala Leu Gly Gly Val Lys Pro Ala
165 170 175

Val	Leu	Thr	Arg	Ser	Gly	Asp	Pro	Ser	Gln	Pro	Leu	Leu	Pro	Gln	His	180	185	190	
Ser	Ser	Leu	Glu	Thr	Gln	Leu	Phe	Cys	Glu	Gln	Gly	Asp	Gly	Gly	Thr	195	200	205	
Glu	Gly	His	Ser	Pro	Ser	Gly	Ile	Leu	Glu	Lys	Ile	Pro	Pro	Asp	Ser	210	215	220	
Glu	Ala	Thr	Leu	Val	Leu	Val	Gly	Arg	Ala	Asp	Phe	Leu	Glu	Gln	Pro	225	230	235	240
Val	Leu	Gly	Phe	Val	Arg	Leu	Gln	Glu	Ala	Ala	Glu	Leu	Glu	Ala	Val	245	250	255	
Glu	Leu	Pro	Val	Pro	Ile	Arg	Phe	Leu	Phe	Val	Leu	Leu	Gly	Pro	Glu	260	265	270	
Ala	Pro	His	Ile	Asp	Tyr	Thr	Gln	Leu	Gly	Arg	Ala	Ala	Ala	Thr	Leu	275	280	285	
Met	Ser	Glu	Arg	Val	Phe	Arg	Ile	Asp	Ala	Tyr	Met	Ala	Gln	Ser	Arg	290	295	300	
Gly	Glu	Leu	Leu	His	Ser	Leu	Glu	Gly	Phe	Leu	Asp	Cys	Ser	Leu	Val	305	310	315	320
Leu	Pro	Pro	Thr	Asp	Ala	Pro	Ser	Glu	Gln	Ala	Leu	Leu	Ser	Leu	Val	325	330	335	
Pro	Val	Gln	Arg	Glu	Leu	Leu	Arg	Arg	Arg	Tyr	Gln	Ser	Ser	Pro	Ala	340	345	350	
Lys	Pro	Asp	Ser	Ser	Phe	Tyr	Lys	Gly	Leu	Asp	Leu	Asn	Gly	Gly	Pro	355	360	365	
Asp	Asp	Pro	Leu	Gln	Gln	Thr	Gly	Gln	Leu	Phe	Gly	Gly	Leu	Val	Arg	370	375	380	
Asp	Ile	Arg	Arg	Arg	Tyr	Pro	Tyr	Tyr	Leu	Ser	Asp	Ile	Thr	Asp	Ala	385	390	395	400
Phe	Ser	Pro	Gln	Val	Leu	Ala	Ala	Val	Ile	Phe	Ile	Tyr	Phe	Ala	Ala	405	410	415	
Leu	Ser	Pro	Ala	Ile	Thr	Phe	Gly	Gly	Leu	Leu	Gly	Glu	Lys	Thr	Arg	420	425	430	
Asn	Gln	Met	Gly	Val	Ser	Glu	Leu	Leu	Ile	Ser	Thr	Ala	Val	Gln	Gly	435	440	445	
Ile	Leu	Phe	Ala	Leu	Leu	Gly	Ala	Gln	Pro	Leu	Leu	Val	Val	Gly	Phe	450	455	460	
Ser	Gly	Pro	Leu	Leu	Val	Phe	Glu	Glu	Ala	Phe	Phe	Ser	Phe	Cys	Glu	465	470	475	480
Thr	Asn	Gly	Leu	Glu	Tyr	Ile	Val	Gly	Arg	Val	Trp	Ile	Gly	Phe	Trp	485	490	495	

Leu Ile Leu Leu Val Val Leu Val Val Ala Phe Glu Gly Ser Phe Leu
 500 505 510
 Val Arg Phe Ile Ser Arg Tyr Thr Gln Glu Ile Phe Ser Phe Leu Ile
 515 520 525
 Ser Leu Ile Phe Ile Tyr Glu Thr Phe Ser Lys Leu Ile Lys Ile Phe
 530 535 540
 Gln Asp His Pro Leu Gln Lys Thr Tyr Asn Tyr Asn Val Leu Met Val
 545 550 555 560
 Pro Lys Pro Gln Gly Pro Leu Pro Asn Thr Ala Leu Leu Ser Leu Val
 565 570 575
 Leu Met Ala Gly Thr Phe Phe Phe Ala Met Met Leu Arg Lys Phe Lys
 580 585 590
 Asn Ser Ser Tyr Phe Pro Gly Lys Leu Arg Arg Val Ile Gly Asp Phe
 595 600 605
 Gly Val Pro Ile Ser Ile Leu Ile Met Val Leu Val Asp Phe Phe Ile
 610 615 620
 Gln Asp Thr Tyr Thr Gln Lys Leu Ser Val Pro Asp Gly Phe Lys Val
 625 630 635 640
 Ser Asn Ser Ser Ala Arg Gly Trp Val Ile His Pro Leu Gly Leu Arg
 645 650 655
 Ser Glu Phe Pro Ile Trp Met Met Phe Ala Ser Ala Leu Pro Ala Leu
 660 665 670
 Leu Val Phe Ile Leu Ile Phe Leu Glu Ser Gln Ile Thr Thr Leu Ile
 675 680 685
 Val Ser Lys Pro Glu Arg Lys Met Val Lys Gly Ser Gly Phe His Leu
 690 695 700
 Asp Leu Leu Leu Val Val Gly Met Gly Gly Val Ala Ala Leu Phe Gly
 705 710 715 720
 Met Pro Trp Leu Ser Ala Thr Thr Val Arg Ser Val Thr His Ala Asn
 725 730 735
 Ala Leu Thr Val Met Gly Lys Ala Ser Thr Pro Gly Ala Ala Ala Gln
 740 745 750
 Ile Gln Glu Val Lys Glu Gln Arg Ile Ser Gly Leu Leu Val Ala Val
 755 760 765
 Leu Val Gly Leu Ser Ile Leu Met Glu Pro Ile Leu Ser Arg Ile Pro
 770 775 780
 Leu Ala Val Leu Phe Gly Ile Phe Leu Tyr Met Gly Val Thr Ser Leu
 785 790 795 800
 Ser Gly Ile Gln Leu Phe Asp Arg Ile Leu Leu Leu Phe Lys Pro Pro
 805 810 815

Lys Tyr His Pro Asp Val Pro Tyr Val Lys Arg Val Lys Thr Trp Arg
 820 825 830
 Met His Leu Phe Thr Gly Ile Gln Ile Ile Cys Leu Ala Val Leu Trp
 835 840 845
 Val Val Lys Ser Thr Pro Ala Ser Leu Ala Leu Pro Phe Val Leu Ile
 850 855 860
 Leu Thr Val Pro Leu Arg Arg Val Leu Leu Pro Leu Ile Phe Arg Asn
 865 870 875 880
 Val Glu Leu Gln Cys Leu Asp Ala Asp Asp Ala Lys Ala Thr Phe Asp
 885 890 895
 Glu Glu Glu Gly Arg Asp Glu Tyr Asp Glu Val Ala Met Pro Val
 900 905 910

<210> 2

<211> 2740

<212> DNA

<213> Homo sapiens

<220>

<223> human anion exchange protein 1 (AE1), band 3 protein

<400> 2

```

cgccatggag gagctgcagg atgattatga agacatgatg gaggagaatc tggagcagga 60
ggaatatgaa gaccagaca tccccgagtc ccagatggag gagccggcag ctcacgacac 120
cgaggcaaca gccacagact accacaccac atcacaccgc ggtaccaca aggtctatgt 180
ggagctgcag gagctggtga tggacgaaaa gaaccaggag ctgagatgga tggaggcggc 240
gcgctgggtg caactggagg agaacctggg ggagaatggg gcctggggcc gcccgacct 300
ctctcacctc accttctgga gcctcctaga gctgcgtaga gtcttcacca aggggtactgt 360
tctcctagac ctgcaagaga cctccctggc tggagtggcc aaccaactgc tagacaggtt 420
tatctttgaa gaccagatcc ggccctcagga ccgagaggag ctgctccggg ccctgctgct 480
taaacacagc cagctggagg agctggaggc cctggggggg gtgaagcctg cagtcttgac 540
acgctctggg gatccttcac agcctctgct cccccaacac tcctcactgg agacacagct 600
cttctgtgag caggagatg ggggcacaga agggcactca ccatctggaa ttctggaaaa 660
gattcccccg gattcagagg ccacgttggt gctagtgggc cgcgccgact tcctggagca 720
gccggtgctg ggcttcgtga ggctgcagga ggcagcggag ctggaggcgg tggagctgcc 780
ggtgcctata cgcttctctt ttgtgttgct gggacctgag gccccccaca tcgattacac 840
ccagcttggc cgggctgctg ccacctcat gtcagagagg gtgttccgca tagatgccta 900
catggctcag agccgagggg agctgctgca ctccctagag ggcttcctgg actgcagcct 960
agtgtgcct cccaccgatg cccctccga gcaggcactg ctcagtctgg tgcctgtgca 1020
gagggagcta cttcgaaggc gctatcagtc cagccctgcc aagccagact ccagcttcta 1080
caagggccta gacttaaag ggggccaga tgacctctg cagcagacag gccagctctt 1140
cgggggcctg gtgcgtgata tccggcgccg ctaccttat tacttgagtg acatcacaga 1200
tgcatcagc cccaggtcc tggctgcgt catcttcac tactttgctg cactgtcacc 1260
cgccatcacc ttccggcgcc tctgggaga aaagaccgg aaccagatgg gagtgtcggg 1320
gctgctgatc tccactgcag tgcaggcat tctcttcgcc ctgctggggg ctcagccct 1380
gcttggtggtc ggcttctcag gacctctgct ggtgtttgag gaagccttct tctcgttctg 1440
cgagaccaac ggtctagagt acatcgtggg ccgcgtgtgg atcggttctt ggctcatcct 1500
gctgggtggtg ttggtggtgg ccttcgaggg tagcttctct gtccgcttca tctcccgcta 1560
taccaggagg atcttctcct tctcatttc cctcatcttc atctatgaga ctttctccaa 1620
gctgatcaag atcttccagg accaccact acagaagact tataactaca acgtgttgat 1680
ggtgccccaa cctcagggcc cctgccccaa cacagccctc ctctcccttg tgctcatggc 1740
cggtaccttc ttctttgcca tgatgctgcg caagttcaag aacagctcct atttccctgg 1800
caagctgcgt cgggtcatcg gggacttcgg ggtccccatc tccatcctga tcatggctct 1860
ggtggatttc ttcattcagg atacctacac ccagaaactc tcggtgcctg atggcttcaa 1920

```

```

gggtgtccaac tcctcagccc ggggctgggt catccaccca ctgggcttgc gttccgagtt 1980
tcccacatctgg atgatgtttg cctccgccct gcctgctctg ctgggtcttca tcctcatatt 2040
cctggagtgct cagatcacca cgctgattgt cagcaaacct gagcgcaaga tgggtcaaggg 2100
ctccggcttc cacctggacc tgctgctggg agtaggcattg ggtgggggtgg ccgccctctt 2160
tgggatgccc tggctcagtg ccaccaccgt gcgttccgtc acccatgcca acgccctcac 2220
tgtcatgggc aaagccagca cccaggggc tgcagcccag atccaggagg tcaaagagca 2280
gcggatcagt ggactcctgg tcgctgtgct tgtgggcctg tccatcctca tggagcccat 2340
cctgtcccgc atccccctgg ctgtactgtt tggcatcttc ctctacatgg gggtcacgtc 2400
gctcagcggc atccagctct ttgaccgcat cttgcttctg ttcaagccac ccaagtatca 2460
cccagatgtg ccctacgtca agcgggtgaa gacctggcgc atgcacttat tcacgggcat 2520
ccagatcatc tgccctggcag tgctgtgggt ggtgaagtcc acgccggcct ccctggccct 2580
gcccttcgtc ctcatcctca ctgtgccgt gcggcgcgtc ctgctgccgc tcattcttcag 2640
gaacgtggag cttcagtgtc tggatgctga tgatgccaag gcaacctttg atgaggagga 2700
aggtcgggat gaatacgacg aagtggccat gcctgtgtga 2740

```

```

<210> 3
<211> 10
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> Description of Artificial Sequence:residues
      536-545 of AE1 protein, predicted alpha-helix

```

```

<400> 3
Thr Phe Ser Lys Leu Ile Lys Ile Phe Gln
  1                   5                   10

```

```

<210> 4
<211> 10
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> Description of Artificial Sequence:peptide mimic
      when used as antigen raises antibodies which bind
      to and cause destruction of pathologically
      adherent erythrocytes

```

```

<220>
<221> MOD_RES
<222> (1)..(10)
<223> Xaa = amino acid charged under physiological
      conditions

```

```

<400> 4
Thr Phe Ser Xaa Leu Ile Xaa Ile Phe Gln
  1                   5                   10

```

```

<210> 5
<211> 14
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> Description of Artificial Sequence:preferred
      native AE1 sequence, peptide including two
      residues on either side of predicted alpha-helix

```

<400> 5
Tyr Glu Thr Phe Ser Lys Leu Ile Lys Ile Phe Gln Asp His
1 5 10

<210> 6
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:peptide mimic
when used as antigen raises antibodies which bind
to and cause destruction of pathologically
adherent erythrocytes

<220>
<221> MOD_RES
<222> (1)..(14)
<223> Xaa = amino acid charged under physiological
conditions

<400> 6
Tyr Xaa Thr Phe Ser Xaa Leu Ile Xaa Ile Phe Gln Xaa Xaa
1 5 10

<210> 7
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:exemplar
peptide

<400> 7
Thr Phe Ser Asp Leu Ile Glu Ile Phe Gln
1 5 10

<210> 8
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:exemplar
peptide

<400> 8
Thr Phe Ser Asp Leu Ile Asp Ile Phe Gln
1 5 10

<210> 9
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:exemplar
peptide

<400> 9
Thr Phe Ser Arg Leu Ile His Ile Phe Gln
1 5 10

<210> 10
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:exemplar
peptide

<400> 10
Thr Phe Ser Asp Leu Ile Lys Ile Phe Gln
1 5 10

<210> 11
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:exemplar
peptide

<400> 11
Thr Phe Ser His Leu Ile Glu Ile Phe Gln
1 5 10

<210> 12
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:exemplar
peptide

<400> 12
Thr Phe Ser Asp Leu Ile Glu Ile Phe Gln
1 5 10

<210> 13
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:exemplar
peptide

<400> 13
 Thr Phe Ser Glu Leu Ile Glu Ile Phe Gln
 1 5 10

<210> 14
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:exemplar peptide

<400> 14
 Thr Phe Ser Arg Leu Ile Arg Ile Phe Gln
 1 5 10

<210> 15
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:exemplar peptide

<400> 15
 Ala Phe Ser Lys Leu Ile Lys Ile Phe Gln
 1 5 10

<210> 16
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:exemplar peptide

<400> 16
 Thr Tyr Ser Asp Leu Ile Asp Ile Phe Gln
 1 5 10

<210> 17
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:exemplar peptide

<400> 17
 Thr Phe Ser Lys Leu Ile Lys Leu Phe Gln
 1 5 10

<210> 18
 <211> 10
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:exemplar
 peptide

 <400> 18
 Thr Phe Ser Asp Leu Ile Lys Ile Phe Asn
 1 5 10

 <210> 19
 <211> 10
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:exemplar
 peptide

 <400> 19
 Thr Phe Ser Asp Leu Val Asp Ile Phe Gln
 1 5 10

 <210> 20
 <211> 10
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:exemplar
 peptide

 <400> 20
 Thr Phe Ala Arg Leu Ile Arg Leu Phe Gln
 1 5 10

 <210> 21
 <211> 10
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:exemplar
 peptide

 <400> 21
 Thr Phe Ser Glu Leu Ile Lys Ile Trp Asn
 1 5 10

 <210> 22
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:peptide
fragment containing amino terminal portion of SEQ
ID NO:5 or 6

<400> 22
Tyr Glu Thr Phe Ser Lys Leu Ile Lys
1 5

<210> 23
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:peptide
fragment containing amino terminal portion of SEQ
ID NO:5 or 6

<400> 23
Tyr Asp Thr Phe Ser Arg Leu Ile Arg
1 5